Personalized immune cell treatment for advanced cancers after failed therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that is metastatic or cannot be removed by surgery, and it has progressed despite standard treatment (or standard treatment isn’t an option).
- Doctors can safely take a tumor sample (biopsy or surgery) to grow the immune cells, and if that area was previously radiated, it must have grown again before sampling.
- You’re 18 or older, willing to sign consent, and able to follow the study visits and treatment plan.
- Your general health and organ tests must be strong enough (including certain heart, lung, blood, liver, and kidney thresholds).
- You must not have HIV, active hepatitis B, or active hepatitis C based on blood tests.
- You must use highly effective birth control during treatment and for months afterward (and follow pregnancy testing rules if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
Hear when a new Epithelial Tumors, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.